Oncotype DX
A 21-gene test that tells most women with early hormone-positive breast cancer whether they can safely skip chemotherapy.
TAILORx (2018): women with recurrence score ≤25 (and >50 years) derive no chemotherapy benefit. RxPONDER extended this to 1-3 positive nodes in postmenopausal women. Exact Sciences. MammaPrint (Agendia) and Prosigna/PAM50 are alternatives.
1.RNA is extracted from the tumour block
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| United States | Medicare and most commercial plans for node-negative and node-positive (1-3) HR+/HER2- early breast cancer | ~$4,500 list price | — |
| United Kingdom | NICE: recommended for ER+/HER2- node-negative and some node-positive early breast cancer (DG58) | not disclosed | — |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Oncotype DX" OR ABSTRACT:"Oncotype DX") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Oncotype DX, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductMammaPrint (70-gene signature)
Shares Gene-expression assay → chemotherapy omission, TAILORx, Companion diagnostics, RNA sequencing & expression profiling.
- TermCompanion diagnostic
Shares A formal regulatory route for validating a biomarker on archived trial samples, A fund for prospective validation of academic biomarkers and companion diagnostics, Companion diagnostics.
- IdeaA commons for leftover trial biospecimens with standard access for approved research
Shares A fund for prospective validation of academic biomarkers and companion diagnostics, Companion diagnostics.
- TermOvarian function suppression (OFS)
Shares RxPONDER (SWOG S1007), HR-positive / HER2-negative breast cancer.
- TechnologySentinel lymph node biopsy
Shares Payer-funded trials that omit surgery or radiotherapy in low-risk patients, NSABP Foundation, HR-positive / HER2-negative breast cancer.
- IdeaAI quantification of HER2-low and HER2-ultralow
Shares A fund for prospective validation of academic biomarkers and companion diagnostics, HR-positive / HER2-negative breast cancer.
- InstitutionBC Cancer
Shares RNA sequencing & expression profiling, HR-positive / HER2-negative breast cancer.
- InstitutionSkåne University Hospital / Lund University Cancer Centre
Shares RNA sequencing & expression profiling, HR-positive / HER2-negative breast cancer.